Processa Pharmaceuticals, Inc.
PCSA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533743
In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Processa Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 5 filings
- 5 insiders, $25.9K in total
- Open-market sells
- 0 filings
- Insiders trading
- 5
- Net value
- +$25.9K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Processa Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Ng George K | Chief Executive Officer | 17,092 | Aug 11, 2026 | 10 |
| Gujrathi Sheila | Director | – | Jul 30, 2026 | 1 |
| Yorke Justin W | Director | 353 | Jul 28, 2026 | 3 |
| Skibsted Russell | Chief Financial Officer | 16,689 | Jul 28, 2026 | 9 |
| Pannu Geraldine | Director | 2,391 | Jul 28, 2026 | 4 |
| Neal James R | Director | 1,021 | Jul 28, 2026 | 4 |
| Lin Patrick | Chief Business - Strategy Off | 13,113 | Jul 28, 2026 | 10 |
| Guy Wendy | Chief Administrative Officer | 14,394 | Jul 28, 2026 | 10 |
| Baluch Khoso | Director | 2,528 | Jul 28, 2026 | 4 |
| Young David | Pres. Research & Development | 21,729 | Jul 1, 2026 | 9 |
| Bigora Sian | Chief Development Officer | 7,481 | May 19, 2026 | 5 |
| Stanker James H | Chief Financial Officer | 6,482 | Aug 2, 2024 | 0 |
| Thompson Virgil | Director | 123,849Indirect | Jul 24, 2023 | 0 |
| Floyd Robert Michael | Chief Operating Officer | 82,267 | Feb 10, 2023 | 0 |
| Islam Khalid | Director | 72,486 | Apr 19, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2022 (view filing) | Apr 6-7 | 2 days | Lin PatrickChief Business - Strategy Off | PPurchase | +2.00K | $3.29 | +$6.59K | +0.5%431.4K after | 2 lots |
| Jan 31, 2022 (view filing) | Jan 27 | 4 days | Yorke Justin WDirector | SSale | −1.85K | $3.30 | −$6.12K | −0.3%532.6K after | |
| Dec 16, 2021 (view filing) | Dec 14 | 2 days | Lin PatrickChief Business - Strategy Off | PPurchase | +3.00K | $4.00 | +$12.0K | +0.7%429.4K after | |
| Dec 7, 2021 (view filing) | Dec 3-6 | 4 days | Yorke Justin WDirector | SSale | −9.70K | $4.78 | −$46.4K | −1.8%534.4K after | 2 lots |
| Dec 7, 2021 (view filing) | Dec 3 | 4 days | Lin PatrickChief Business - Strategy Off | PPurchase | +3.50K | $4.80 | +$16.8K | +0.8%426.4K after | |
| Aug 30, 2021 (view filing) | Aug 26 | 4 days | Lin PatrickChief Business - Strategy Off | PPurchase | +4.00K | $6.02 | +$24.1K | +1.0%422.9K after |